CGEM Q3 2022 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q3 2022 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$25M

EPS (Diluted)

$-0.54

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$617M

Total Liabilities

$31M

Stockholders' Equity

$586M

Cash & Equivalents

$243M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$30M	-$18M	-62.0%
Net Income	-$25M	-$17M	-43.0%